Relapse after glofitamab has a poor prognosis and rates of CD20 loss are high

Samuel Grigg; Adrian Minson; Elizabeth Prins; Michael J Dickinson

doi:10.1111/bjh.19455

Relapse after glofitamab has a poor prognosis and rates of CD20 loss are high

Br J Haematol. 2024 May 8. doi: 10.1111/bjh.19455. Online ahead of print.

Authors

Samuel Grigg^{1

2}, Adrian Minson^{1

2}, Elizabeth Prins², Michael J Dickinson^{1

2}

Affiliations

¹ Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.
² Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.

PMID: 38720530
DOI: 10.1111/bjh.19455

Abstract

We reviewed cases with aggressive B-cell non-Hodgkin lymphoma who relapsed or progressed following glofitamab. The prognosis was poor, with low rates of response to subsequent salvage therapies, and a median overall survival of 4.1 months from the time of progression. There were high rates of CD20 loss (59%) at the time of relapse. In a field where CD20 × CD3 bispecific antibodies are entering routine clinical use, our experience highlights a potential means of resistance. It illustrates both the need to further characterise mechanisms of CD20 loss, and to pursue clinical trials of novel non-CD20-directed treatments in this cohort.

Keywords: immunotherapy; lymphoid malignancies; lymphomas.